Journal Home
Search for

Volume 76, Issue 4, Pages 984-990 (15 March 2010)


View previous. 5 of 56 View next.

True Local Recurrence Rate in the Conserved Breast After Magnetic Resonance Imaging–Targeted Radiotherapy

Elisabeth Whipp, F.R.C.R.Corresponding Author Informationemail address, Mark Beresford, F.R.C.R., Elinor Sawyer, Ph.D., Michael Halliwell, Ph.D.

Received 2 December 2008; received in revised form 24 February 2009; accepted 3 March 2009. published online 06 July 2009.

Purpose

Better accuracy of local radiotherapy may substantially improve local control and thus long-term breast cancer survival. Magnetic resonance imaging (MRI) has high resolution and sensitivity in breast tissue and may depict the tumor bed more accurately than conventional planning techniques. A postoperative complex (POCx) comprises all visible changes thought to be related to surgery within the breast and acts as a surrogate for the tumor bed. This study reports on local recurrence rates after MRI-assisted radiotherapy planning to ensure adequate coverage of the POCx.

Methods and Materials

Simple opposed tangential fields were defined by surface anatomy in the conventional manner in 221 consecutive patients. After MRI, fields were modified by a single radiation oncologist to ensure encompassment of the POCx with a 10-mm margin. Genetic analysis was performed on all local relapses (LRs) to distinguish true recurrences (TRs) from new primaries (NPs).

Results

This was a high risk cohort at 5 years: only 9.5% were classified as low risk (St Gallen): 43.4% were Grade 3 and 19.9% had surgical margins <1 mm; 62.4% of patients received boosts. Adjustments of standard field margins were required in 69%. After a median follow-up of 5 years, there were 3 LRs (1.3%) as the site of first relapse in 221 patients, comprising two TRs (0.9%) and one NP (0.4%).

Conclusions

Accurate targeting of the true tumor bed is critical. MRI may better define the tumor bed.

 University Bristol Hospitals Trust, Bristol, United Kingdom

 Guys, Kings, St Thomas' Cancer Centre/Molecular and Population Genetics Laboratory, Cancer Research UK, London, United Kingdom

Corresponding Author InformationReprint requests to: Elisabeth Whipp, FRCR, University Bristol Hospitals Trust, Marlborough Street, Bristol BS1 3NU, United Kingdom. Tel: (+44) 1179282417; Fax (+44) 1179734211

 Conflict of interest: none.

PII: S0360-3016(09)00462-3

doi:10.1016/j.ijrobp.2009.03.026


View previous. 5 of 56 View next.